Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
CANINE PARVOVIRUS, LIVE
Zoetis Ireland Limited
QI07AD01
CANINE PARVOVIRUS, LIVE
Unknown
Lyophilisate and solvent for suspension for injection
POM
Canine
Canine parvovirus vaccine
Immunological - Live Vaccine
Authorised
2016-05-06
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus P lyophilisate and solvent for suspension for injection for dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1ml contains: ACTIVE SUBSTANCES: SOLVENT: Water for injections (_Aqua ad iniectabilia_) 1 ml * Tissue culture infectious dose 50 % For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. The visual appearance is as follows: Lyophilisate: spongy matter of white colour. Solvent: clear colourless liquid. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of dogs from 6 weeks of age: to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus. Onset of immunity: 3 weeks after the first vaccination Duration of immunity: At least three years following the primary vaccination course 4.3 CONTRAINDICATIONS None. LYOPHILISATE (LIVE ATTENUATED): MINIMUM MAXIMUM Canine parvovirus Type 2b, strain CPV-2b Bio 12/B 10 4.3 TCID 50 * 10 6.6 TCID 50 HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 21/11/2016_ _CRN 7024216_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress. Immunological responses to CPV may be delayed due to maternally derived antibody interference. However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to Przeczytaj cały dokument